Serial #98202327
LIVE

Serial Number

98202327

Owner

Utah Cancer Specialists, P.C.

Attorney

Lester K. Essig

First Use Date

Sep 12, 2022

Filing Date

Sep 28, 2023

Add to watchlist:

No watchlists yet
View on USPTO

Serial #98202327 Trademark

Serial Number: 98202327 • Registration: 8082159

Serial #98202327 is a trademark filed by Utah Cancer Specialists, P.C. on September 28, 2023. The trademark is classified under Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Utah Cancer Specialists, P.C.

Suite C230
Salt Lake City, UT 84124

Entity Type: 99

Trademark Details

Filing Date

September 28, 2023

Registration Date

December 30, 2025

First Use Anywhere

September 12, 2022

First Use in Commerce

September 12, 2022

Published for Opposition

November 11, 2025

Goods & Services

Medical services; medical services in the nature of diagnosis, treatment, management and prevention of cancer, blood-related diseases and illnesses; medical imaging services in the fields of oncology, hematology, cancer, blood-related diseases and illnesses; providing medical, medical oncology and hematology treatments for cancer, blood-related diseases and illnesses; providing medical, oncology and hematology treatments for cancer, blood-related diseases and illnesses, namely, immunotherapy, use of monoclonal antibodies, drug therapy, targeted drug therapy, biological therapy, chemotherapy, oral chemotherapy, and hormonal therapy; providing radiation treatments for cancer, blood-related diseases and illnesses; providing radiation treatments for cancer, blood-related diseases and illnesses, namely, diagnostic imaging, PET imaging, CT imaging, external beam radiation therapy, intensity-modulated radiation therapy (IMRT), image guided therapy (GRT), peptide receptor radionuclide therapy (PRRT), and brachytherapy; medical clinic services; health counseling, palliative care services, rehabilitative care, namely, physical rehabilitation; providing guidance relating to nutrition for those with cancer, blood-related diseases and illnesses; patient individual medical counseling regarding medical options, treatment options, care options, medical side-effects, medical scheduling, medical support, stress reduction for health purposes, and related medical information; providing online medical and health information in the fields of medicine, oncology, hematology, cancer, blood-related diseases and illnesses, diagnosis, treatment, management and prevention of cancer, blood-related diseases and illnesses; preparation of prescriptions in pharmacies; dispensing of medications and oral medications; medical testing in the fields of medicine, oncology, hematology, cancer, tumors, solid tumors, liquid tumors, blood-related diseases and illnesses; providing online medical and health information in the fields of patient, caregiver and family medical support, medical resources and medical information

Educational services, namely, providing and arranging classes, educational programs and educational learning centers featuring instruction in the fields of medicine, oncology, hematology, cancer, cancer types, blood-related diseases and illnesses, diagnosis, treatment, management and prevention of cancer, blood-related diseases and illnesses, and patient, caregiver and family support, and distribution of educational resources in connection therewith

Financial and insurance counseling in the nature of providing advice regarding payment options, financial aid, financial options and insurance for patients

Organizing and providing emotional support services and organizing, providing and conducting support groups for those with cancer, blood-related diseases and illnesses; providing patient advocate services and patient advocate counseling in the field of cancer, blood-related diseases and illnesses

Clinical research and scientific studies in the fields of medicine, oncology, hematology, cancer, tumors, blood-related diseases and illnesses; scientific research and scientific research testing in the fields of medicine, oncology, hematology, cancer, tumors, solid tumors, liquid tumors, blood-related diseases and illnesses; scientific research in the nature of conducting clinical trials in the fields of medicine, oncology, hematology, cancer, tumors, solid tumors, liquid tumors, blood-related diseases and illnesses

Filing History

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 28, 2026 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 28, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 28, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 28, 2026 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 30, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 30, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 9, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 8, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 8, 2025 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 9, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 9, 2025 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 9, 2025 GNFN
FINAL REFUSAL E-MAILED
Apr 9, 2025 GNFR
FINAL REFUSAL WRITTEN
Apr 9, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 17, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 17, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 17, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 17, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 25, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 25, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 25, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 23, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 23, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 23, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 23, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 23, 2024 CNRT
ASSIGNED TO EXAMINER
May 21, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Oct 13, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 12, 2023 NWOS
NEW APPLICATION ENTERED
Oct 2, 2023 NWAP